Annovis Bio, Inc. (ANVS)
NYSE · Common stock · Pharmaceutical Preparations
As of Oct 21, 3:14 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
ANVS trades thinly or has a short history, so some panels below have little to show.
Follow ANVS in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ANVS and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ANVS at a glance
Key statistics
$41.75M
Market capitalization
- Previous close
- $0.9783
- Open
- $0.9950
- Day range
- $0.9900 – $1.03
- Volume
- 415.5K
- Average volume (30 sessions)
- 914.6K
- Shares outstanding
- 42.68M
- Earnings per share
- $(1.16)
- Beta (1 year, vs SPY)
- 1.62
Where the price sits in its year
52-week range
1% of the range
- Below the 52-week high
- -81.7%
- Above the 52-week low
- +5.8%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $1.17-16.4%
- 50-day average
- $1.39-29.4%
- 200-day average
- $2.02-51.6%
Between the conventional 30 and 70 bands.
-7.7%
1 week
-17.8%
1 month
-43.8%
3 months
-71.7%
Year to date
-50.6%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ANVS
ANVS on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ANVS.
See the plans →
Every planScreen names like ANVS
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ANVS
Put ANVS on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ANVS
See whether there is an open premium alert on ANVS, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ANVS headlines
- Annovis to Host Corporate Update Webinar on September 2, 2026
GlobeNewswire Inc. · Aug 25, 2026
- Annovis Announces Two Presentations at the CTAD 2025 Conference
GlobeNewswire Inc. · Nov 24, 2025
- Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
GlobeNewswire Inc. · Mar 25, 2025
- Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc. · Feb 7, 2025
- Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
GlobeNewswire Inc. · Feb 5, 2025
- Annovis Bio, Inc. Announces Proposed Public Offering
GlobeNewswire Inc. · Jan 31, 2025
- Annovis to Host Year-End Investor Webcast on December 11, 2024
GlobeNewswire Inc. · Nov 25, 2024
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire Inc. · Sep 5, 2024
SEC Form 4, most recent first
Insider filings
Hoffman Michael B
+18.8K
Director · Open-market purchase
$33.93K · May 20, 2026
Hoffman Michael B
+2.6K
Director · Open-market purchase
$4.48K · May 20, 2026
Hoffman Michael B
+54.9K
Director · Open-market purchase
$104.37K · May 20, 2026
Hoffman Michael B
+713.8K
Director · Open-market purchase
$1.50M · Apr 2, 2026
Hoffman Michael B
+15.0K
Director · Open-market purchase
$63.60K · Dec 8, 2025
Hoffman Michael B
+30.0K
Director · Open-market purchase
$130.19K · Dec 8, 2025
Hoffman Michael B
+9.2K
Director · Open-market purchase
$35.42K · Nov 24, 2025
Hoffman Michael B
+1.5K
Director · Open-market purchase
$6.15K · Nov 24, 2025
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
- Exchange
- NYSE
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Malvern, PA
- Employees
- 7
- Listed since
- Jan 29, 2020
- Website
- annovisbio.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.